Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 50

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 50
---
 no par value (the “Common Stock”) at a purchase price of
$3.00 per share, representing an 18% premium to the closing share price of the Common Stock of $2.54 on the date of execution (the “Bayshore
Financing”). The Company received the initial payment of $1 million for the Bayshore Financing on May 20, 2025. In July 2025, an
additional 666,666 common shares were issued for $2 million received.

We
have incurred significant losses and negative cash flows from operations since inception and expect to incur additional losses until
such time that we can generate significant revenue and profit, which we do not expect to occur in the near future. We had negative cash
flow from operations of approximately $1.6 million for the six months ended June 30, 2025. As of June 30, 2025, we had cash and cash
equivalents of approximately $0.8 million and an accumulated deficit of approximately $37.8 million.

We
currently expect that our cash and cash equivalents will only be sufficient to fund our operations, development plans, and capital expenditures
through the third quarter of 2026. As such, there is substantial doubt about the Company’s ability to continue as a going concern.

We
did not have any material non-cancellable contractual obligations as of June 30, 2025.

16

Cash
Flows

The
following table provides information regarding our cash flows for the periods presented:

    Six Months Ended June 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $(1,559,577) 
    $(3,462,258)
  
    Financing activities 
     1,047,769  
     5,344,936 
  
    Net change in cash 
    $(511,808) 
    $1,882,678 

Net
Cash from Operating Activities

The
cash used in operating activities resulted primarily from our net losses, stock-based compensation expenses and changes in components
of accounts payable, accrued liabilities, and prepaid expenses.

For
the six months ended June 30, 2025, operating activities used $1.6 million of cash, primarily due to a net loss of $7.2 million,
stock compensation costs of $6.0 million and by a $0.4 million change in accounts payable,